Basilea Capital Markets Day
11 April 2024
Park Hyatt, Zurich
Event-Video
Program
We were delighted to have Professor Oliver A. Cornely and Professor Thomas L. Holland as our guest speakers.
April 11
13:00
Check-in start
14:00
Welcome
David Veitch, CEO
14:15
Financial position & business model
Adesh Kaul, CFO
incl. Q&A
14:30
The new assets in our drug pipeline: Fosmanogepix, BAL2062 and tonabacase
Marc Engelhardt, M.D., Ph.D., CMO
15:00
Coffee-Break
15:30
Treating infectious diseases: progress, current limitations and future needs
Invasive fungal infections
Professor Oliver A. Cornely, Professor of Translational Research, Faculty of Medicine, University of Cologne
Staphylococcus aureus bacteremia
Professor Thomas L. Holland, Associate Professor of Medicine, Infectious Diseases, Department of Medicine, Duke University
16:30
Round table and Q&A
16:50
Key Take Aways & Wrap Up
David Veitch, CEO
17:00
Networking & Apéro
18:00
End
Interested in a meeting?
If you have further questions or would like to request a meeting with the Management or IR team, please do not hesitate to reach out to Ms. Dung Tran, Investor Relations Coordinator, at NgocDung.Tran@basilea.com .
Event-Highlights
Speakers
Oliver A. Cornely
M.D., Ph.D.
Professor of Translational Research, Faculty of Medicine, University of Cologne
Thomas L. Holland
M.D., Ph.D.
Associate Professor of Medicine, Infectious Diseases, Department of Medicine, Duke University
David Veitch
Chief Executive Officer at Basilea
Adesh Kaul
Chief Financial Officer at Basilea
“Basilea is living in exciting times.
We’re on the verge of something big, in the changing world of anti-infectives."
David Veitch | CEO Basilea Pharmaceutica
Basilea Pharmaceutica Ltd, Allschwil
Ms. Dung Tran
P: +41 61 606 12 58
ngocdung.tran@basilea.com